Q3 2020 Nordic Nanovector ASA Earnings Call Transcript
Good morning, everyone, and welcome to the Q3 presentation from Nordic Nanovector. My name is Lars Nieba, I'm the interim CEO of Nordic Nanovector. I have with me today our Chairman, Jan Egberts; our CFO, Malene Brondberg; and our COO, Marco Renoldi.
Let me directly start with our Q3 highlights. As a lot of you might have read already, we have a positive outcome from our PARADIGME interim analysis. The Independent Review Committee who looked on the data recommended to focus on a single arm and investigating our 40/15 dosing regimen. We have approval of the protocol amendments to PARADIGME proceeding as planned and completed in best recruiting countries. To remind everybody, it was designed to enlarge our eligible patient population and to increase the rate of enrollment.
Our pivotal Phase IIb PARADIGME trial with Betalutin is progressing in third-line follicular lymphoma. We do have 59 patients enrolled as of the 18th of November 2020. I would like to add here that our activities, which we have pursued and where we'll come later
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
